Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John N Nacey

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
The New Zealand Medical Journal|November 11, 2011
Revised status of PSA testing in the early detection and treatment of prostate cancerDavid S Lamb, Brett Delahunt, John N Nacey
Pathology|September 22, 2007
Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtypeBrett Delahunt, Peter B Bethwaite, John N Nacey
The New Zealand Medical Journal|February 20, 2014
Improving outcomes for New Zealand men with prostate cancerJohn N Nacey, Brett Delahunt, Stephen D Mark
The New Zealand Medical Journal|January 13, 2012
PSA testing--who should decide when it is performed?David S Lamb, Brett Delahunt, John N Nacey
BJU International|June 26, 2004
Differences in prostate disease symptoms and visits to the general practitioner among three ethnic groups in New ZealandMarion A Gray, Peter Crampton, Philip Weinstein, et al.
Annals of Clinical Biochemistry|May 1, 2004
Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2010 and the Abbott Architect i2000Marion A Gray, Russell R Cooke, Philip Weinstein, et al.
Human Pathology|May 25, 2007
The evolution of collagen expression in sarcomatoid renal cell carcinomaBrett Delahunt, Peter B Bethwaite, Margaret R E McCredie, et al.
Histopathology|October 15, 2013
Total submission of pelvic lymphadenectomy tissues removed during radical prostatectomy for prostate cancer increases lymph node yield and detection of micrometastasesJoanna Perry-Keene, Peter Ferguson, Hemamali Samaratunga, et al.
Histopathology|April 23, 2014
Effective maybe, but is it cost-effective? A replyJoanna Perry-Keene, Peter Ferguson, Hemamali Samaratunga, et al.
Histopathology|March 19, 2016
Reply: Gleason and Fuhrman no longer make the gradeBrett Delahunt, Lars Egevad, Hemamali Samaratunga, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
The New Zealand Medical Journal|November 11, 2011
Revised status of PSA testing in the early detection and treatment of prostate cancerDavid S Lamb, Brett Delahunt, John N Nacey
Pathology|September 22, 2007
Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtypeBrett Delahunt, Peter B Bethwaite, John N Nacey
The New Zealand Medical Journal|February 20, 2014
Improving outcomes for New Zealand men with prostate cancerJohn N Nacey, Brett Delahunt, Stephen D Mark
The New Zealand Medical Journal|January 13, 2012
PSA testing--who should decide when it is performed?David S Lamb, Brett Delahunt, John N Nacey
BJU International|June 26, 2004
Differences in prostate disease symptoms and visits to the general practitioner among three ethnic groups in New ZealandMarion A Gray, Peter Crampton, Philip Weinstein, et al.
Annals of Clinical Biochemistry|May 1, 2004
Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2010 and the Abbott Architect i2000Marion A Gray, Russell R Cooke, Philip Weinstein, et al.
Human Pathology|May 25, 2007
The evolution of collagen expression in sarcomatoid renal cell carcinomaBrett Delahunt, Peter B Bethwaite, Margaret R E McCredie, et al.
Histopathology|October 15, 2013
Total submission of pelvic lymphadenectomy tissues removed during radical prostatectomy for prostate cancer increases lymph node yield and detection of micrometastasesJoanna Perry-Keene, Peter Ferguson, Hemamali Samaratunga, et al.
Histopathology|April 23, 2014
Effective maybe, but is it cost-effective? A replyJoanna Perry-Keene, Peter Ferguson, Hemamali Samaratunga, et al.
Histopathology|March 19, 2016
Reply: Gleason and Fuhrman no longer make the gradeBrett Delahunt, Lars Egevad, Hemamali Samaratunga, et al.
Pageof 3